Swedish Orphan Biovitrum AB

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000872095
SEK
453.20
7.4 (1.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

421.29 k

Shareholding (Mar 2024)

FII

0.00%

Held by 1 FIIs

DII

100.00%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Healthy long term growth as Net Sales has grown by an annual rate of 13.10%

 
2

With a growth in Net Profit of 72.48%, the company declared Very Positive results in Jun 26

3

With ROE of 19.82%, it has a expensive valuation with a 3.84 Price to Book Value

4

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 165,053 Million (Large Cap)

stock-summary
P/E

19.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.38

stock-summary
Return on Equity

20.24%

stock-summary
Price to Book

3.91

Revenue and Profits:
Net Sales:
7,842 Million
(Quarterly Results - Jun 2026)
Net Profit:
1,098 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.03%
0%
2.03%
6 Months
14.5%
0%
14.5%
1 Year
65.4%
0%
65.4%
2 Years
68.48%
0%
68.48%
3 Years
134.42%
0%
134.42%
4 Years
110.5%
0%
110.5%
5 Years
186.08%
0%
186.08%

Swedish Orphan Biovitrum AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.10%
EBIT Growth (5y)
12.54%
EBIT to Interest (avg)
7.83
Debt to EBITDA (avg)
1.86
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.50
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.39%
ROE (avg)
10.77%

Valuation key factors

Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
3.84
EV to EBIT
20.12
EV to EBITDA
9.33
EV to Capital Employed
2.97
EV to Sales
5.98
PEG Ratio
0.20
Dividend Yield
NA
ROCE (Latest)
14.77%
ROE (Latest)
19.82%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 27.00% vs 13.47% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 73.19% vs 183.04% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,842.00",
          "val2": "6,175.00",
          "chgp": "27.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,143.00",
          "val2": "2,152.00",
          "chgp": "46.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "204.00",
          "val2": "216.00",
          "chgp": "-5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-355.00",
          "val2": "-237.00",
          "chgp": "-49.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,098.00",
          "val2": "634.00",
          "chgp": "73.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "240.60%",
          "val2": "204.50%",
          "chgp": "3.61%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.50% vs 17.64% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -87.73% vs 61.02% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28,238.00",
          "val2": "26,027.00",
          "chgp": "8.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11,536.00",
          "val2": "9,538.00",
          "chgp": "20.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "813.00",
          "val2": "1,240.00",
          "chgp": "-34.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7,136.00",
          "val2": "-195.00",
          "chgp": "-3,559.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "476.00",
          "val2": "3,879.00",
          "chgp": "-87.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "285.00%",
          "val2": "223.40%",
          "chgp": "6.16%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - YoYstock-summary

Jun'26
Jun'25
Change(%)
Net Sales
7,842.00
6,175.00
27.00%
Operating Profit (PBDIT) excl Other Income
3,143.00
2,152.00
46.05%
Interest
204.00
216.00
-5.56%
Exceptional Items
-355.00
-237.00
-49.79%
Consolidate Net Profit
1,098.00
634.00
73.19%
Operating Profit Margin (Excl OI)
240.60%
204.50%
3.61%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2026 is 27.00% vs 13.47% in Jun 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2026 is 73.19% vs 183.04% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
28,238.00
26,027.00
8.50%
Operating Profit (PBDIT) excl Other Income
11,536.00
9,538.00
20.95%
Interest
813.00
1,240.00
-34.44%
Exceptional Items
-7,136.00
-195.00
-3,559.49%
Consolidate Net Profit
476.00
3,879.00
-87.73%
Operating Profit Margin (Excl OI)
285.00%
223.40%
6.16%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 8.50% vs 17.64% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -87.73% vs 61.02% in Dec 2024

stock-summaryCompany CV
About Swedish Orphan Biovitrum AB stock-summary
stock-summary
Swedish Orphan Biovitrum AB
Pharmaceuticals & Biotechnology
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Company Coordinates stock-summary
Company Details
Tomtebodavagen 23A , SOLNA None : 112 76
stock-summary
Tel: 46 8 697200046 73 3666599
stock-summary
Registrar Details